$APGE
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Michael Thomas Henderson
CEO
196
Employees
$132.69
Current Price
$3.85B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 2 | $14,103,840.00 | 106,400 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 9 | $16,204,366.66 | 131,900 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 16 | $18,472,941.85 | 159,400 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 25 | $20,941,244.89 | 188,900 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 100 | $85.89 | $8,589.00 | View Details |
| Apr 1, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 2,702 | $85.33 | $230,561.66 | View Details |
| Apr 1, 2026 | Dambkowski Carl Chief Medical Officer | Sale | 2,698 | $84.31 | $227,468.38 | View Details |
| Apr 1, 2026 | Henderson Jane Chief Financial Officer | Sale | 1,100 | $85.46 | $94,006.00 | View Details |
| Apr 1, 2026 | Henderson Jane Chief Financial Officer | Sale | 900 | $84.46 | $76,014.00 | View Details |
61 more transactions available โ create a free account to see 12 months of history | ||||||
Showing 21โ25 of 25 transactions
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history